cagrilintide phase 3 Cagrilintide–semaglutide (CagriSema) as an add-on to basal insulin in adults with type 2 diabetes (REIMAGINE 3): a randomised, double-blind, placebo-controlled, multicentre, study Three new phase 3 REIMAGINE
Description
The glycemic improvements were equally impressive, with 73.5% of combination participants achieving HbA1c levels at or below 6.5%
Durelli, L

D., Seaman, H
The Mediterranean diet, rich in anti-inflammatory and antioxidant components, is associated with reduced oxidative stress and thyroid inflammation (Osowiecka And Myszkowska-Ryciak 2023)

The FDA approves none of these peptides for human use, and that matters for safety